TY - JOUR T1 - Risks and etiology of bacterial vaginosis revealed by species dominance network analysis JF - medRxiv DO - 10.1101/2020.05.23.20104208 SP - 2020.05.23.20104208 AU - Zhanshan (Sam) Ma AU - Aaron M. Ellison Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/26/2020.05.23.20104208.abstract N2 - BV (bacterial vaginosis) influences 20-40% of women but its etiology is still poorly understood. An open question about the BV is which of the hundreds of bacteria found in the human vaginal microbiome (HVM) are the causal pathogens of BV? Existing attempts to identify them have failed for at least two reasons: (i) a focus on species per se that ignores species interactions; (ii) a lack of systems-level understanding of the HVM. Here, we recast the question of microbial causality of BV by asking if there are any reliable ‘signatures’ of community composition (or poly-microbial ‘cults’) associated with it? We apply a new framework (species dominance network analysis by Ma & Ellison (2019: Ecological Monographs) to detect critical structures in HVM networks associated with BV risks and etiology. We reanalyzed the metagenomic datasets of a mixed-cohort of 25 BV patients and healthy women. In these datasets, we detected 15 trio-motifs that occurred exclusively in BV patients. We failed to find any of these 15 trio-motifs in three additional cohorts of 1535 healthy women. Most member-species of the 15 trio motifs are BV-associated anaerobic bacteria (BVAB), Ravel’s community-state type indicators, or the most dominant species; virtually all species interactions in these trios are high-salience skeletons, suggesting that those trios are strongly connected ‘cults.’ The presence of trio motifs unique to BV may act as indicators for its personalized diagnosis and could help elucidate a more mechanistic interpretation of its risks and etiology.Single sentence summary 15 trio motifs unique to the BV (bacterial vaginosis) may act as indicators for personalized BV diagnosis, risk prediction and etiological study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data sources have been listed in the main manuscript. ER -